Protagonist Therapeutics, INC Form 4 insider transactions

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, sold 2,712 shares of common stock to cover tax obligations related to restricted stock unit settlement.

Protagonist Therapeutics Director William D. Waddill exercised options and sold 12,000 common shares on October 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Director William D. Waddill sold 4,000 shares of common stock at $64.25 per share on September 22, 2025, as part of a pre-arranged 10b5-1 trading plan.

Protagonist Therapeutics CEO Dinesh Patel reports gifting 620 common shares.

Protagonist Therapeutics Director William D. Waddill sold 4,000 shares of common stock for $59.25 per share under a pre-arranged trading plan.

Protagonist Therapeutics' President and CEO, Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock for a weighted average price of $54.78 per share under a Rule 10b5-1 trading plan.

Protagonist Therapeutics' President and CEO, Dinesh V. Patel, acquired 25,000 shares from vested performance stock units and subsequently sold a total of 52,444 shares, including those to cover tax obligations.

Protagonist Therapeutics President and CEO, Dinesh V. Patel, Ph.D., reported a charitable donation of 5,000 shares of common stock on July 16, 2025.

Protagonist Therapeutics, Inc. CEO and President Dinesh V. Patel, Ph.D., reported gifting a total of 1,355 shares of common stock to his grandchildren in mid-June 2025, as disclosed in a recent SEC Form 4 filing.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, executed a series of stock option exercises and subsequent common stock sales on June 9 and June 10, 2025, realizing substantial profits.

Harold E. Selick, a director of Protagonist Therapeutics, exercised stock options to acquire 10,725 shares of common stock at $1.16 per share on April 28, 2025.

Asif Ali, CFO of Protagonist Therapeutics, sold 1,756 shares of common stock on April 22, 2025, to cover tax withholding obligations.

Director William D. Waddill of Protagonist Therapeutics sold 4,000 shares of common stock at a price of $54.25 per share on March 17, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, exercised stock options and sold shares of common stock on March 13, 2025.

Asif Ali, CFO of Protagonist Therapeutics, reports exercising stock options and selling shares on March 12, 2025.

Dinesh V. Patel, CEO of Protagonist Therapeutics, exercised stock options to acquire 24,000 shares of common stock on March 5, 2025.

Dinesh V. Patel, CEO of Protagonist Therapeutics, sold 5,359 shares of common stock on February 19, 2025, to cover tax withholding obligations.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold a portion of his shares to cover tax obligations related to the settlement of restricted stock units.

Protagonist Therapeutics CEO, Dinesh V. Patel, sold 12,636 shares to cover tax obligations related to the settlement of restricted stock units.

Protagonist Therapeutics' Chief Financial Officer, Asif Ali, sold shares to cover tax obligations related to the settlement of restricted stock units.

Director William D. Waddill of Protagonist Therapeutics acquired 5,130 shares of common stock and 6,584 stock options on January 2, 2025.

Sarah A. O'Dowd, a director at Protagonist Therapeutics, received a grant of restricted stock units and stock options on January 2, 2025.

Director Lewis T. Williams acquired 5,130 shares of common stock and 6,584 stock options in Protagonist Therapeutics on January 2, 2025.

Harold E. Selick, a director at Protagonist Therapeutics, acquired 5,130 shares of common stock and options to purchase 6,584 shares on January 2, 2025.

Protagonist Therapeutics CEO, Dinesh V. Patel, Ph.D., received a grant of restricted stock units and stock options on January 2, 2025.

Director Bryan Giraudo reports receiving restricted stock units and stock options from Protagonist Therapeutics.

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, reports the acquisition of restricted stock units and stock options.

Protagonist Therapeutics' Chief Financial Officer, Asif Ali, acquired 31,779 shares of common stock and 38,520 stock options on January 2, 2025.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, exercised stock options and sold shares in multiple transactions over two days.

Protagonist Therapeutics' Chief Development Officer, Suneel Gupta, exercised stock options and sold shares to cover the exercise costs.